Laboratorios Rovi (ROVI) Stock Price, Fundamentals & Analysis
Price
59.15 EUR
-0.59%
Last trade: Sep 25, 2026, 05:35 PM GMT+2
Updated: Sep 27, 2026, 11:47 AM GMT+2
Price history
Over the past year ROVI traded between 53.65 EUR and 85.55 EUR, closing at 59.15 EUR on Sep 25, 2026.
Key statistics
| Market cap | 3.03B EUR |
|---|---|
| P/E ratio (TTM) | 16.3 |
| Forward P/E | 17.6 |
| EPS (TTM) | 3.62 EUR |
| Dividend yield | 1.62% |
| Annual dividend | 0.96 EUR |
| Ex-dividend date | Jul 13, 2026 |
| Payout ratio | 26% |
| 52-week range | 53.1 – 86.7 |
| 52-week change | 5% |
| Beta | 0.24 |
| Price / book | 4.32 |
| Revenue (TTM) | 773.05M EUR |
| Revenue growth (YoY) | 20% |
| Gross margin | 64.7% |
| Operating margin | 9.4% |
| Profit margin | 24% |
| Return on equity | 28.7% |
| Debt / equity | 15 |
| Volume | 99,539 |
| Average volume | 115,433 |
| Next earnings | Nov 5, 2026 |
| Exchange | MCE |
Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,470
- Headquarters
- Pozuelo de Alarcón, Spain
- Website
- rovi.es
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR.
Overview
Laboratorios Rovi (ROVI) is a stock traded on Bolsa de Madrid in the Healthcare sector. Currently, the current price is 59.15 EUR, market capitalisation is 3.03B EUR, the trailing P/E is 16.3, the dividend yield is 1.62%. The 52-week price range is 53.1 – 86.7.
A detailed overview for this security is being prepared.
Latest news & filings
No recent headlines.
Related
More on ROVI
Track ROVI in your portfolio
Hold ROVI at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free